Friday, 6 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Singapore Cold Chain Logistics Market Set to Surpass Valuation of US$ 3,942.30 Million By 2035 | Astute Analytica

View original at globenewswire.com
“SATS Ltd’s Food Solutions division saw revenue grow by $33.8 million in the final quarter of FY2025, largely driven by the recovery of chilled meal catering for aviation and institutional clients.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The regulated electricity tariff for Jan-Mar 2026 is set at 26.71 cents per kWh

    80% confidence

  • Red Lion 2's automation is projected to increase warehouse productivity by 100% compared to manual processes

    80% confidence

  • The Singapore cold chain logistics market is valued at approximately USD 2,010 million, with a projected trajectory to breach USD 3,942.30 million by 2035, growing at a CAGR of 7.40% during the forecast period 2026–2035

    80% confidence

  • Authorities recorded a foodborne illness rate of 22.8 cases per 100,000 population in 2024

    80% confidence

  • Vegetable farm productivity hit 231.4 tons per hectare in 2025

    80% confidence

  • Smart refrigeration systems in the Singapore cold chain logistics market are now delivering energy savings of up to 30%

    80% confidence

  • The nation now sources food from 187 countries, a diversification that requires sophisticated chilled supply chains

    80% confidence

  • Integrated IT platforms in new facilities reduce customer lead times by 40%

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com
Singapore Cold Chain Logistics Market Set to Surpass Valuation of US$ 3,942.30 Million By 2035 | Astute Analytica — Source | Via News | ViaNews EU